AU2016359722B2 - Thermostable FGF2 polypeptide, use thereof - Google Patents

Thermostable FGF2 polypeptide, use thereof Download PDF

Info

Publication number
AU2016359722B2
AU2016359722B2 AU2016359722A AU2016359722A AU2016359722B2 AU 2016359722 B2 AU2016359722 B2 AU 2016359722B2 AU 2016359722 A AU2016359722 A AU 2016359722A AU 2016359722 A AU2016359722 A AU 2016359722A AU 2016359722 B2 AU2016359722 B2 AU 2016359722B2
Authority
AU
Australia
Prior art keywords
fgf2
lys
leu
gly
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016359722A
Other languages
English (en)
Other versions
AU2016359722A1 (en
Inventor
Lukas BALEK
David Bednar
Michaela BOSAKOVA
Jan Brezovsky
Radka Chaloupkova
Jiri Damborsky
Pavel DVORAK
Petr Dvorak
Livia EISELLEOVA
Zaneta KONECNA
Pavel Krejci
Zbynek Prokop
Eva SEBESTOVA
Veronika Stepankova
Pavel VANACEK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enantis SRO
Masarykova Univerzita
Original Assignee
Enantis S R O
Masarykova Univerzita
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enantis S R O, Masarykova Univerzita filed Critical Enantis S R O
Publication of AU2016359722A1 publication Critical patent/AU2016359722A1/en
Application granted granted Critical
Publication of AU2016359722B2 publication Critical patent/AU2016359722B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
AU2016359722A 2015-11-27 2016-10-03 Thermostable FGF2 polypeptide, use thereof Active AU2016359722B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15196802 2015-11-27
EP15196802.1 2015-11-27
PCT/EP2016/073567 WO2017089016A1 (en) 2015-11-27 2016-10-03 Thermostable fgf2 polypeptide, use thereof

Publications (2)

Publication Number Publication Date
AU2016359722A1 AU2016359722A1 (en) 2018-07-19
AU2016359722B2 true AU2016359722B2 (en) 2020-09-17

Family

ID=54754475

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016359722A Active AU2016359722B2 (en) 2015-11-27 2016-10-03 Thermostable FGF2 polypeptide, use thereof

Country Status (13)

Country Link
US (1) US11746135B2 (enExample)
EP (1) EP3380508B1 (enExample)
JP (1) JP7131772B2 (enExample)
KR (1) KR102650035B1 (enExample)
CN (1) CN108779158A (enExample)
AU (1) AU2016359722B2 (enExample)
BR (1) BR112018010676A2 (enExample)
CA (1) CA3006388C (enExample)
ES (1) ES2824479T3 (enExample)
LT (1) LT3380508T (enExample)
PL (1) PL3380508T3 (enExample)
SG (1) SG11201804402WA (enExample)
WO (1) WO2017089016A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112190531B (zh) * 2019-06-19 2022-11-01 湖北医药学院 抗细胞衰老制剂及其制备方法和应用、细胞及其构建方法
KR20220142994A (ko) * 2019-09-19 2022-10-24 노쓰웨스턴 유니버시티 인간 유도 다능성 줄기 세포의 비용 효과적인 배양 배지 및 프로토콜
KR102428940B1 (ko) * 2019-11-25 2022-08-03 한국해양과학기술원 온도안정성 및 단백질 분해효소 저항성을 향상시킨 fgf2 폴리펩타이드 및 그 용도
CN114746436B (zh) * 2019-11-25 2024-07-02 韩国海洋科学技术院 改善温度稳定性和蛋白酶抗性的fgf2多肽及其用途
CZ309550B6 (cs) * 2021-06-15 2023-04-05 Enantis s.r.o Termostabilní polypeptid na bázi FGF18 a jeho použití
GB2616475A (en) * 2022-03-11 2023-09-13 Multus Biotechnology Ltd Engineered fibroblast growth factor variants
KR20250110924A (ko) * 2022-11-25 2025-07-21 비티엘 헬쓰케어 테크놀로지스 에이.에스. 개선된 안정성을 갖는 fgf-2 폴리펩티드, fgf-2 폴리펩티드를 제조하는 방법 및 그의 용도
CN116041478A (zh) * 2022-12-19 2023-05-02 太东(镇江)生物科技有限公司 基于大肠杆菌体外纯化系统的人重组热稳定蛋白fgf2制备方法
KR20240173282A (ko) * 2023-06-02 2024-12-11 (주)피앤피바이오팜 고안정성 활성지속형 염기성 섬유아세포 성장인자 변이체를 이용한 줄기세포 유래 엑소좀의 제조방법
KR20240173283A (ko) * 2023-06-02 2024-12-11 (주)피앤피바이오팜 고안정성 활성지속형 염기성 섬유아세포 성장인자 변이체를 이용한 줄기세포의 배양방법
WO2025141173A1 (en) 2023-12-28 2025-07-03 Meatable B.V. Methods of increasing differentiation and/or fat accumulation in cells
EP4613865A1 (en) 2024-03-05 2025-09-10 The Cultivated B. GmbH Animal collagen from non-animal sources
WO2025186217A1 (en) 2024-03-05 2025-09-12 The Cultivated B. Gmbh Animal collagen from non-animal sources

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995008630A1 (en) * 1993-09-24 1995-03-30 American Cyanamid Company Surface loop structural analogues of fibroblast growth factors
US6083706A (en) * 1997-02-26 2000-07-04 Ciblex Corporation Inhibitors of leaderless protein export
WO2004069298A1 (en) * 2003-02-06 2004-08-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Fgf-2 derived proteins for the preparation of biomaterials or medical devices such as stents
US20070212332A1 (en) * 2005-08-11 2007-09-13 Department Of Veterans Affairs Methods for accelerating bone repair
US20100221232A1 (en) * 2005-06-14 2010-09-02 United States Government As Represented By The Department Of Veterans Affairs Composition and methods for osteogenic gene therapy
EP2333074A1 (en) * 2009-12-14 2011-06-15 Robert Steinfeld Substances and methods for the treatment of lysosmal storage diseases
WO2012158244A2 (en) * 2011-03-01 2012-11-22 Humanzyme Inc. Thermostable variants of fibroblast growth factors
WO2013090919A1 (en) * 2011-12-16 2013-06-20 Wisconsin Alumni Research Foundation Fgf-2 having enhanced stability
WO2013184962A1 (en) * 2012-06-07 2013-12-12 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
EP2930181A1 (en) * 2014-04-07 2015-10-14 Miltenyi Biotec GmbH Fibroblast growth factor muteins with increased activity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU614137B2 (en) 1988-06-06 1991-08-22 Takeda Chemical Industries Ltd. Stabilized fgf composition and production thereof
US5202311A (en) 1988-08-19 1993-04-13 Children's Medical Center Corporation Stabilized fgf composition
CA2020654A1 (en) 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
US5143829A (en) 1990-03-29 1992-09-01 California Biotechnology Inc. High level expression of basic fibroblast growth factor having a homogeneous n-terminus
US7754686B2 (en) 2000-08-31 2010-07-13 Novartis Vaccines And Diagnostics, Inc. Stabilized FGF formulations containing reducing agents
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
WO2008038287A2 (en) * 2006-09-28 2008-04-03 Hepacore Ltd. N-terminal fgf variants having increased receptor selectivity and uses thereof
US7659379B1 (en) 2007-05-24 2010-02-09 Florida State University Research Foundation, Inc. Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency
US8461111B2 (en) 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
US8481308B2 (en) 2010-07-01 2013-07-09 Regenerative Research Foundation Methods for culturing undifferentiated cells using sustained release compositions
US9925270B2 (en) 2011-11-28 2018-03-27 The Regents Of The University Of California bFGF-polymer conjugates, methods for making the same and applications thereof
WO2013090911A1 (en) 2011-12-16 2013-06-20 Wisconsin Alumni Research Foundation Method for supporting human pluri potent stem cell cultures comprising culturing the cells in a medium comprising thermostable fgf - 1 proteins

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995008630A1 (en) * 1993-09-24 1995-03-30 American Cyanamid Company Surface loop structural analogues of fibroblast growth factors
US6083706A (en) * 1997-02-26 2000-07-04 Ciblex Corporation Inhibitors of leaderless protein export
WO2004069298A1 (en) * 2003-02-06 2004-08-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Fgf-2 derived proteins for the preparation of biomaterials or medical devices such as stents
US20100221232A1 (en) * 2005-06-14 2010-09-02 United States Government As Represented By The Department Of Veterans Affairs Composition and methods for osteogenic gene therapy
US20070212332A1 (en) * 2005-08-11 2007-09-13 Department Of Veterans Affairs Methods for accelerating bone repair
EP2333074A1 (en) * 2009-12-14 2011-06-15 Robert Steinfeld Substances and methods for the treatment of lysosmal storage diseases
WO2012158244A2 (en) * 2011-03-01 2012-11-22 Humanzyme Inc. Thermostable variants of fibroblast growth factors
WO2013090919A1 (en) * 2011-12-16 2013-06-20 Wisconsin Alumni Research Foundation Fgf-2 having enhanced stability
WO2013184962A1 (en) * 2012-06-07 2013-12-12 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
EP2930181A1 (en) * 2014-04-07 2015-10-14 Miltenyi Biotec GmbH Fibroblast growth factor muteins with increased activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARCELA BUCHTOVA ET AL, "Instability restricts signaling of multiple fibroblast growth factors", CMLS CELLULAR AND MOLECULAR LIFE SCIENCES., DE, (2015-02-18), vol. 72, no. 12, doi:10.1007/s00018-015-1856-8, ISSN 1420-682X, pages 2445 - 2459 *

Also Published As

Publication number Publication date
JP2019500414A (ja) 2019-01-10
US20200270320A1 (en) 2020-08-27
PL3380508T3 (pl) 2021-07-12
KR102650035B1 (ko) 2024-03-20
WO2017089016A1 (en) 2017-06-01
KR20180080335A (ko) 2018-07-11
SG11201804402WA (en) 2018-06-28
BR112018010676A2 (pt) 2019-04-09
CA3006388C (en) 2023-05-09
LT3380508T (lt) 2020-11-10
CN108779158A (zh) 2018-11-09
CA3006388A1 (en) 2017-06-01
US11746135B2 (en) 2023-09-05
EP3380508A1 (en) 2018-10-03
ES2824479T3 (es) 2021-05-12
EP3380508B1 (en) 2020-07-22
JP7131772B2 (ja) 2022-09-06

Similar Documents

Publication Publication Date Title
AU2016359722B2 (en) Thermostable FGF2 polypeptide, use thereof
AU2016359722A1 (en) Thermostable FGF2 polypeptide, use thereof
KR100205078B1 (ko) 염기성 섬유 아세포 성장인자 및 이의 생산방법
CN111454350B (zh) 一种重组纤连蛋白突变体及其应用
CN110950967B (zh) 抗人血清白蛋白纳米抗体与il-2融合蛋白及制备方法
CN116589560B (zh) 生物合成重组人源化纤连蛋白以及制备方法
WO2025148254A1 (zh) 生物合成人体结构性材料xvii型胶原蛋白的方法
US7294706B2 (en) Identification of receptor and heparin binding sites in FGF4 by structure-based mutagenesis
EP3168230B1 (en) Gdf-5 mutant for inducing cartilage formation
Song et al. High-efficiency production of bioactive recombinant human fibroblast growth factor 18 in Escherichia coli and its effects on hair follicle growth
JP2025516910A (ja) 生合成による人体構造性材料の製造方法
JP4729740B2 (ja) 受容体特異性を変化させたミュータント増殖因子およびそれを含有する医薬組成物
US12344666B2 (en) PDGF mutants and methods of use thereof
CN113735961B (zh) 一类雌激素相关受体β突变体及其应用
US20250353888A1 (en) Thermostable FGF10 Polypeptide or Fragment Thereof and Use Thereof
Shah Towards a structural understanding of the iRhom/ADAM17 complex
KR20250110924A (ko) 개선된 안정성을 갖는 fgf-2 폴리펩티드, fgf-2 폴리펩티드를 제조하는 방법 및 그의 용도
CZ309550B6 (cs) Termostabilní polypeptid na bázi FGF18 a jeho použití
Chiu Study of Structural Relationship Between Human Ribosomal Proteins P1 and P2
Hisatake Mapping the Lectin-Like Activity of
KR20190005240A (ko) Tgf-베타 슈퍼패밀리의 ab6 패밀리 디자이너 리간드를 포함하는 골 및 연골 질환 치료용 조성물 및 그의 이용

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)